Santhera's Single-Asset Bet: What Vamorolone's Pipeline Concentration Means for European Rare Disease Patients
Swiss specialty pharmaceutical company Santhera Pharmaceuticals faces significant pipeline concentration risk, with its entire commercial future effectively staked on a single asset — vamorolone — for Duchenne Muscular Dystrophy. As the company has already licensed out its Japan and Asia-Pacific rights to Nxera, any setback to vamorolone's European trajectory could leave thousands of DMD patients without a key treatment alternative and Santhera with little commercial fallback.
ViaNews Editorial Team (Europe)•